Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy

• DOI: 10.1007/s12325-023-02616-9
• Publication Date: 2023-08-12T14:02:01Z
• Authors: Hidetoshi Hayashi; Makoto Nishio; Michiko Takahashi; Hiroaki Tsuchiya; Mami Kasahara-Kir...
• Keywords: Osimertinib

Docetaxel is an established standard therapy after osimertinib and platinum-based doublet chemotherapy (Pt-doublet) for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor gene (EGFR) mutation. To facilitate future therapeutic developments in these patients treatment Pt-doublet, we estimated the outcomes of currently used post-treatment therapies. Data NSCLC who received at least one medication Pt-doublet between April 2008 August 2021 were extracted from Medical Vision claims database. The duration (DoT) (first Pt-doublet) overall survival (OS) estimated. index date was first day on which prescribed. In total, 731 (mean age 64 years) screened. most frequent post-treatments docetaxel-based (30.2%), immune checkpoint inhibitor (ICI) alone combination (17.2%), first-/second-generation EGFR-tyrosine kinase inhibitors (16.7%), (16.3%), (5.2%). median DoT OS (95% confidence interval) all 3.5 (3.27, 3.77) 10.3 (9.3, 12.1) months, respectively, reflecting (3.8 months) (10.0 chemotherapy. Among regimens, ICIs resulted numerically shortest [2.77 (2.33, 3.00) months] longest [4.40 (3.47, 5.67) DoT. post-treated [7.07 (5.40, 9.90) rechallenged (12.27 months), followed by (11.70 months). a subset analysis first-line second-line as well immediately osimertinib, those had Given limited real-world efficacy EGFR-mutant resistant to chemotherapy, development more highly potent therapies warranted.